No Data
"increasing holdings at the bottom" helped the international medical limit, and the Shenzhen Stock Exchange issued a letter of concern as soon as possible.
On September 16, the international medical announcement, the company received the actual controller Liu Jianshen submitted a "proposal to all employees of the company to increase their holdings of the company's shares." Affected by this news, international medicine continued to rise after opening high yesterday, rising all the way to 11.03 yuan per share, with a net inflow of 235 million yuan. Performance frequent losses, the stock price has halved at the beginning of this year, the medical beauty track wind blowing, a number of concept stocks ushered in a wave of rise. In the first half of the year, the share prices of listed companies hit record highs. On June 2, International Medicine set a five-year high of 21.66 yuan per share in intraday trading, with the company's market capitalization.
The share price has halved! The real controller shouted that employees should "increase their holdings at the bottom" and increase the limit of international medicine.
The so-called "holding at the bottom" is generally a means by which listed companies are determined to maintain the stock price for watch protection, which can usually produce good results in a short period of time. Last night, International Medicine issued an announcement revealing the "bottom-up" initiative of the company's real controllers. Today, the international medical market continued to rise after opening high. as of press time, the share price rose by the limit of 11.03 yuan per share. On September 16, the international medical announcement, the company received the actual controller Liu Jianshen submitted a "proposal to all employees of the company to increase their holdings of the company's shares." Liu Jianshen, the controller of the company, promised that, in accordance with the relevant operating rules of this initiative,
Fund position trend: Zheng Lei increased his position in these stocks in the second quarter (list)
Zhenxing Research Institute, July 20 Huitianfu Fund Zheng Lei's fund announced the report, the synthesis of its funds' financial results, the proportion of Hong Kong stocks has increased significantly, Kang Fang Bio-B, Fosun Pharmaceuticals and so on have been increased. Li Ning, Hagia Medical, Kanglong Huacheng and other newly entered the top ten positions. In addition, individual stocks in the medical device industry have attracted more attention. Compared with the last quarter, Fosun Pharmaceuticals and other companies have increased their holdings, while Opcom, Emick and East Fulong have newly entered the top 10 positions; the pharmaceutical industry sector has been reduced, Zhifei Biotech, Changchun High-tech, Hengrui Pharmaceuticals, etc. have withdrawn from the top ten positions, while Pharmaceutical Kant and Kellein have been reduced; at present, their funds have taken a comprehensive position.